Sceberras, V.
Attico, E.
Bianchi, E.
Galaverni, G.
Melonari, M.
Corradini, F.
Fantacci, M.
Ribbene, A.
Losi, L.
Balò, S.
Lazzeri, M.
Trombetta, C.
Rizzo, M.
Manfredini, R.
Barbagli, G.
Pellegrini, G. http://orcid.org/0000-0001-9861-0736
Funding for this research was provided by:
Esperia Bank Group ("Regenerative Medicine of urethra" from Esperia Trust)
Regione Lombardia ("Lombardia è Ricerca" Milano, November 8, 2018)
Ministry of Education, University and Research; IRMI (CTN01_00177_888744)
Article History
Received: 1 May 2019
Accepted: 27 June 2019
First Online: 9 July 2019
Compliance with ethical standards
:
: G. Pellegrini is member of the Board of Directors, R&D Director of Holostem Terapie Avanzate and J-TEC consultant. V. Sceberras is employee of Holostem Terapie Avanzate. E. Attico, M. Melonari, G. Galaverni, M. Fantacci, F. Corradini, G. Barbagli, S. Balò, C. Trombetta, M. Rizzo, L. Losi, E. Bianchi, R. Manfredini, A. Ribbene and M. Lazzeri declare that they have no conflict of interest.
: The study will be submitted to AIFA (Italian Drug Agency) for clinical trial approval.
: Informed consent was obtained from all donors and will be obtained by individual participants included in the study.